Citations (73)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Huijun Jiang & Zhibing Wang. (2023) Prognostic role of the controlling nutritional status (CONUT) score in patients with biliary tract cancer: a meta-analysis. Annals of Medicine 55:2.
Read now
Read now
Reem D Mahmood, Kathryn Graham, Jack Gleeson, Richard A Hubner, Juan W Valle & Mairéad G McNamara. (2023) Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data. Immunotherapy 15:7, pages 517-530.
Read now
Read now
Lei Yang, Juan Zhong, Wenbo Wang & Fuxiang Zhou. (2023) Prognostic Nutritional Index Associates with Immunotherapy Response in Patients with Metastatic Biliary Tract Cancer. Nutrition and Cancer 75:2, pages 696-706.
Read now
Read now
Li Yang, Yanwei He & Xiaoming Li. (2022) Sarcopenia Predicts Relevant Clinical Outcomes in Biliary Tract Cancer Patients: A Systematic Review and Meta-Analysis. Nutrition and Cancer 74:9, pages 3274-3283.
Read now
Read now
Aakansha Singh & Anjana Dwivedi. (2022) Circulating miRNA and cell-free DNA as a potential diagnostic tool in early detection of biliary tract cancer: a meta-analysis. Biomarkers 27:5, pages 399-406.
Read now
Read now
Poshita-Kumari Seesaha, Kang-Xin Wang, Guo-Qun Wang, Ting-Yun Cui, Feng-Jiao Zhao, Lan-Lan Pan, Xiang-Cheng Li, Yong-Qian Shu & Xiao-Feng Chen. (2021) Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer. OncoTargets and Therapy 14, pages 1873-1882.
Read now
Read now
Xiaoyan Lv, Zongxin Zhang & Wenbin Yuan. (2021) Pretreatment Prognostic Nutritional Index (PNI) as a Prognostic Factor in Patients with Biliary Tract Cancer: A Meta-Analysis. Nutrition and Cancer 73:10, pages 1872-1881.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico & Giovanni Brandi. (2021) FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Review of Gastroenterology & Hepatology 15:5, pages 567-574.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) Recent advances of immunotherapy for biliary tract cancer. Expert Review of Gastroenterology & Hepatology 15:5, pages 527-536.
Read now
Read now
Scott H. Waddell & Luke Boulter. (2021) Developing models of cholangiocarcinoma to close the translational gap in cancer research. Expert Opinion on Investigational Drugs 30:4, pages 439-450.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Giorgio Frega & Giovanni Brandi. (2021) Experimental HER2- targeted therapies for biliary tract cancer. Expert Opinion on Investigational Drugs 30:4, pages 389-399.
Read now
Read now
Daniel Neureiter, Christian Mayr & Tobias Kiesslich. (2020) How do we choose the appropriate chemotherapeutic agents for biliary tract cancer?. Expert Opinion on Pharmacotherapy 21:3, pages 243-245.
Read now
Read now
Giovanni Brandi, Alessandro Rizzo, Filippo Gustavo Dall’Olio, Cristina Felicani, Giorgio Ercolani, Matteo Cescon, Giorgio Frega, Simona Tavolari, Andrea Palloni, Stefania De Lorenzo, Francesca Abbati, Veronica Mollica, Angela Dalia Ricci & Carla Serra. (2020) Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. International Journal of Hyperthermia 37:1, pages 479-485.
Read now
Read now
Articles from other publishers (60)
Laura Sahyoun, Kay Chen, Cynthia Tsay, George Chen & Petr Protiva. (2024) Clinical and socioeconomic determinants of survival in biliary tract adenocarcinomas. World Journal of Gastrointestinal Oncology 16:4, pages 1374-1383.
Crossref
Crossref
Yu Zhou, Zhuoran Liu, Yonglang Cheng, Jing Li & Wenguang Fu. (2024) Prognostic value of the modified Glasgow prognostic score in biliary tract cancer patients: a systematic review and meta-analysis. Journal of Gastrointestinal Surgery 28:4, pages 559-565.
Crossref
Crossref
Masaaki Kagoura, Shin Kobayashi, Motohiro Kojima, Masashi Kudo, Motokazu Sugimoto, Masaru Konishi & Naoto Gotohda. (2024) Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone. European Journal of Surgical Oncology 50:3, pages 107980.
Crossref
Crossref
Cecilia Monge, Changqing Xie, Yuta Myojin, Kelley L. Coffman‐D'Annibale, Donna Hrones, Gagandeep Brar, Sophie Wang, Anuradha Budhu, William D. Figg, Maggie Cam, Richard Finney, Elliot B. Levy, David E. Kleiner, Seth M. Steinberg, Xin Wei Wang, Bernadette Redd, Bradford J. Wood & Tim F. Greten. (2024) Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma. Cancer Medicine 13:3.
Crossref
Crossref
Alexander Ney, Daniel C. Osei‐Bordom, Andres Garcia‐Sampedro, Pilar Acedo, Giuseppe K. Fusai, Martyn Stott, Phillip Hopley, Chandni Patel, Lucy Oldfield, William Greenhalf, Eithne Costello & Stephen P. Pereira. 2024. Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e. Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e
291
320
.
Funda Meric-Bernstam, Vicky Makker, Ana Oaknin, Do-Youn Oh, Susana Banerjee, Antonio González-Martín, Kyung Hae Jung, Iwona Ługowska, Luis Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yan Ma, Soham Puvvada, Norah Shire & Jung-Yun Lee. (2024) Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. Journal of Clinical Oncology 42:1, pages 47-58.
Crossref
Crossref
Hossein Taghizadeh, Yawen Dong, Thomas Gruenberger & Gerald W. Prager. (2024) Perioperative and palliative systemic treatments for biliary tract cancer. Therapeutic Advances in Medical Oncology 16.
Crossref
Crossref
Jin Ho Choi, Hwanhee Park, Joo Kyung Park, Jong Kyun Lee, Kyu Taek Lee & Kwang Hyuck Lee. (2024) Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers. Therapeutic Advances in Medical Oncology 16.
Crossref
Crossref
Wanqing Wen, Michael Mumma & Wei Zheng. (2023) Temporal Trends of Stages and Survival of Biliary Tract Cancers in the United States and Associations with Demographic Factors. Cancer Epidemiology, Biomarkers & Prevention 32:11, pages 1660-1667.
Crossref
Crossref
Heather N. Lynch, Jordan S. Kozal, Melissa J. Vincent, Rachel D. Freid, Evan M. Beckett, Sarah Brown, Claire Mathis, Rita S. Schoeny & Andrew Maier. (2023) Systematic review of the human health hazards of propylene dichloride. Regulatory Toxicology and Pharmacology 144, pages 105468.
Crossref
Crossref
Hon-Yi Lin, Chih-Chia Yu, Chen-Lin Chi, Chang-Kuo Wei, Wen-Yao Yin, Chih-En Tseng & Szu-Chin Li. (2023) Peptidylarginine Deiminase Type 2 Predicts Tumor Progression and Poor Prognosis in Patients with Curatively Resected Biliary Tract Cancer. Cancers 15:16, pages 4131.
Crossref
Crossref
Wattana Leowattana, Tawithep Leowattana & Pathomthep Leowattana. (2023) Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer. World Journal of Gastrointestinal Oncology 15:6, pages 959-972.
Crossref
Crossref
Xueyan Cao, Yang Yang, Wei Zhou, Yue Wang, Xue Wang, Xianxiu Ge, Fei Wang, Fangfang Zhou, Xueting Deng & Lin Miao. (2023) Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation. BMC Cancer 23:1.
Crossref
Crossref
Mohamedraed Elshami, Fasih A. Ahmed, Hanna Kakish, Jonathan J. Hue, Richard S. Hoehn, Luke D. Rothermel, David Bajor, Amr Mohamed, Jennifer E. Selfridge, John B. Ammori, Jeffrey M. Hardacre, Jordan M. Winter & Lee M. Ocuin. (2023) Trends and disparities in the utilization of systemic chemotherapy in patients with metastatic hepato-pancreato-biliary cancers. HPB 25:2, pages 239-251.
Crossref
Crossref
Ali Tayebi, Faranak Olamaeian, Arash Pour Mohammad, Milad Gholizadeh Mesgarha, Leila Asef-Kabiri, Farid Moradian, Behrad Seyedesfahani & Mohammad Esmaeil Akbari. (2023) Epidemiological Study of Hepatopancreatobiliary Sarcoma in Iran, 2010 - 2014. International Journal of Cancer Management 15:12.
Crossref
Crossref
Nivedita Sharma, Anjali Tomar & P. K. Tiwari. 2023. Gallbladder Cancer. Gallbladder Cancer
201
235
.
Ka Shing Cheung, Yan Wang Matthew Yeung, Wing Sum Wong, Bofei Li, Wai Kay Seto & Wai K. Leung. (2022) Statins associate with lower risk of biliary tract cancers: A systematic review and meta‐analysis. Cancer Medicine 12:1, pages 557-568.
Crossref
Crossref
Lu Zou, Yang Yang, Biyu Zhou, Weijian Li, Ke Liu, Guoqiang Li, Huijie Miao, Xiaoling Song, Jiahua Yang, Yajun Geng, Maolan Li, Runfa Bao & Yingbin Liu. (2022) tRF-3013b inhibits gallbladder cancer proliferation by targeting TPRG1L. Cellular & Molecular Biology Letters 27:1.
Crossref
Crossref
Xiulan Peng, Xia Wang, Li Hua & Rui Yang. (2022) Prognostic and Clinical Value of the Systemic Immune-Inflammation Index in Biliary Tract Cancer: A Meta-Analysis. Journal of Immunology Research 2022, pages 1-11.
Crossref
Crossref
Jill Koshiol, Binbing Yu, Shaum M. Kabadi, Katherine Baria & Rachna T. Shroff. (2022) Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015. BMC Cancer 22:1.
Crossref
Crossref
Chengkai Jiang, Yang Li, Yongsheng Li, Liguo Liu, Xu-an Wang, Wenguang Wu, Runfa Bao, Hao Weng, Maolan Li, Yajun Geng, Yijun Shu & Yingbin Liu. (2022) Fibrinogen promotes gallbladder cancer cell metastasis and extravasation by inducing ICAM1 expression. Medical Oncology 40:1.
Crossref
Crossref
Gina Kim, Jiyue Qin, Charles B. Hall & Haejin In. (2022) Association Between Socioeconomic and Insurance Status and Delayed Diagnosis of Gastrointestinal Cancers. Journal of Surgical Research 279, pages 170-186.
Crossref
Crossref
Giorgia Alvisi, Alberto Termanini, Cristiana Soldani, Federica Portale, Roberta Carriero, Karolina Pilipow, Guido Costa, Michela Polidoro, Barbara Franceschini, Ines Malenica, Simone Puccio, Veronica Lise, Giovanni Galletti, Veronica Zanon, Federico Simone Colombo, Gabriele De Simone, Michele Tufano, Alessio Aghemo, Luca Di Tommaso, Clelia Peano, Javier Cibella, Matteo Iannacone, Rahul Roychoudhuri, Teresa Manzo, Matteo Donadon, Guido Torzilli, Paolo Kunderfranco, Diletta Di Mitri, Enrico Lugli & Ana Lleo. (2022) Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. Journal of Hepatology 77:5, pages 1359-1372.
Crossref
Crossref
Hossein Taghizadeh & Gerald W. Prager. (2022) Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer. Current Cancer Drug Targets 22:8, pages 639-650.
Crossref
Crossref
Do-Youn Oh, Kyung-Hun Lee, Dae-Won Lee, Jeesun Yoon, Tae-Yong Kim, Ju-Hee Bang, Ah-Rong Nam, Kyoung-Seok Oh, Jae-Min Kim, Young Lee, Violeta Guthrie, Patricia McCoon, Weimin Li, Song Wu, Qu Zhang, Marlon C Rebelatto & Jin Won Kim. (2022) Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. The Lancet Gastroenterology & Hepatology 7:6, pages 522-532.
Crossref
Crossref
Ye Chen, Baoxia Zhang, Chang Liu, Ye Cao, Cheng Lyu & Meng Qiu. (2022) Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis. BMJ Open 12:4, pages e051421.
Crossref
Crossref
Felix Thol, Simon Johannes Gairing, Carolin Czauderna, Thomas Thomaidis, Thomas Gamstätter, Yvonne Huber, Johanna Vollmar, Johanna Lorenz, Maurice Michel, Fabian Bartsch, Lukas Müller, Roman Kloeckner, Peter Robert Galle, Marcus-Alexander Wörns, Jens Uwe Marquardt, Markus Moehler, Arndt Weinmann & Friedrich Foerster. (2022) Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 4:3, pages 100417.
Crossref
Crossref
Alessandro Rizzo, Angela Dalia Ricci, Antonio Cusmai, Silvana Acquafredda, Giuseppe De Palma, Giovanni Brandi & Gennaro Palmiotti. (2022) Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology 29:2, pages 551-564.
Crossref
Crossref
文 左. (2022) Research Progress of FGFR Small Molecule Inhibitors for Cholangiocarcinoma. Hans Journal of Medicinal Chemistry 10:01, pages 27-38.
Crossref
Crossref
Katherine Baria, Enrico N. De Toni, Binbing Yu, Zhuoxin Jiang, Shaum M. Kabadi & Matteo Malvezzi. (2022) Worldwide Incidence and Mortality of Biliary Tract Cancer. Gastro Hep Advances 1:4, pages 618-626.
Crossref
Crossref
A. A. Gritskevich, B. N. Gurmikov, T. P. Baitman, A. N. Shipilova, A. A. Paichadze & A. V. Chzhao. (2021) Cholangiocarcinogenesis and targeted therapy for cholangiocarcinoma. Meditsinskiy sovet = Medical Council:20, pages 101-109.
Crossref
Crossref
Nikunj Patel, Xandra Lie, Chad Gwaltney, Nana Rokutanda, Afsaneh Barzi, Davide Melisi, Teresa Macarulla, Makoto Ueno, Seung Tae Kim, Oren Meyers, Christina Workman, Melinda Bachini & Gordon Cohen. (2021) Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. Oncology and Therapy 9:2, pages 557-573.
Crossref
Crossref
Angela Dalia Ricci & Alessandro Rizzo. (2021) Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?. Medicina 57:12, pages 1301.
Crossref
Crossref
Qiyi Zhang, Xingyu Liu, Shumei Wei, Lufei Zhang, Yang Tian, Zhenzhen Gao, Ming Jin & Sheng Yan. (2021) Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. Frontiers in Oncology 11.
Crossref
Crossref
Xiaofeng Chen, Deqiang Wang, Jing Liu, Jingrong Qiu, Jun Zhou, Jieer Ying, Yan Shi, Zhaoxia Wang, Haizhou Lou, Jiuwei Cui, Jingdong Zhang, Yunpeng Liu, Fengjiao Zhao, Lanlan Pan, Jianyi Zhao, Dongqin Zhu, Shiqing Chen, Xiangcheng Li, Xue Li, Liuqing Zhu, Yang Shao & Yongqian Shu. (2021) Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. Journal for ImmunoTherapy of Cancer 9:11, pages e003214.
Crossref
Crossref
Yuan Gao, Yi LiuLi SunXiwu OuyangChunfu ZhuXihu Qin. (2021) MAD2L1 Functions As a Novel Diagnostic and Predictive Biomarker in Cholangiocarcinoma. Genetic Testing and Molecular Biomarkers 25:11, pages 685-695.
Crossref
Crossref
Audrey E Kam, Ashiq Masood & Rachna T Shroff. (2021) Current and emerging therapies for advanced biliary tract cancers. The Lancet Gastroenterology & Hepatology 6:11, pages 956-969.
Crossref
Crossref
Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee & Sang Myung Woo. (2021) RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. Journal of Clinical Medicine 10:20, pages 4652.
Crossref
Crossref
Lindsay A. Hunter & Heloisa P. Soares. (2021) Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers 13:20, pages 5074.
Crossref
Crossref
Leticia Colyn, Marina Bárcena‐Varela, Gloria Álvarez‐Sola, M. Ujue Latasa, Iker Uriarte, Eva Santamaría, Jose M. Herranz, Alvaro Santos‐Laso, Maria Arechederra, Mikel Ruiz de Gauna, Patricia Aspichueta, Matteo Canale, Andrea Casadei‐Gardini, Maria Francesconi, Simone Carotti, Sergio Morini, Leonard J. Nelson, Maria J. Iraburu, Chaobo Chen, Bruno Sangro, Jose J.G. Marin, Maria L. Martinez‐Chantar, Jesus M. Banales, Robert Arnes‐Benito, Meritxell Huch, John M. Patino, Altaf A. Dar, Mehdi Nosrati, Julen Oyarzábal, Felipe Prósper, Jesus Urman, Francisco Javier Cubero, Christian Trautwein, Carmen Berasain, Maite G. Fernandez‐Barrena & Matias A. Avila. (2021) Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology 73:6, pages 2380-2396.
Crossref
Crossref
Alessandro Rizzo. (2021) Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina 57:5, pages 458.
Crossref
Crossref
Alessandro Rizzo & Giovanni Brandi. (2021) Novel Targeted Therapies for Advanced Cholangiocarcinoma. Medicina 57:3, pages 212.
Crossref
Crossref
Jianchun Xiao, Li Wang, Tao Hong, Binglu Li, Wei Liu, Qiang Qu, Chaoji Zheng & Xiaodong He. (2021) The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study. Journal of Oncology 2021, pages 1-7.
Crossref
Crossref
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers 13:3, pages 558.
Crossref
Crossref
Nai-Jung Chiang, Li-Tzong Chen, Yan-Shen Shan, Chun-Nan Yeh & Ming-Huang Chen. (2021) Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 11:1, pages 97.
Crossref
Crossref
Cameron J. Herting & Gregory B. Lesinski. 2023. Immune Strategies for Gastrointestinal Cancer. Immune Strategies for Gastrointestinal Cancer
3
28
.
Makoto Ueno, Masafumi Ikeda, Takashi Sasaki, Fumio Nagashima, Nobumasa Mizuno, Satoshi Shimizu, Hiroki Ikezawa, Nozomi Hayata, Ryo Nakajima & Chigusa Morizane. (2020) Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer 20:1.
Crossref
Crossref
Ayhan Ulusakarya, Abdoulaye Karaboué, Oriana Ciacio, Gabriella Pittau, Mazen Haydar, Pamela Biondani, Yusuf Gumus, Amale Chebib, Wathek Almohamad & Pasquale F. Innominato. (2020) A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer 20:1.
Crossref
Crossref
Dmitry V. Yakovlev, Dina S. Farrakhova, Artem A. Shiryaev, Kanamat T. Efendiev, Maxim V. Loschenov, Liana M. Amirkhanova, Dmitry O. Kornev, Vladimir V. Levkin, Igor V. Reshetov & Victor B. Loschenov. (2021) New approaches to diagnostics and treatment of cholangiocellular cancer based on photonics methods. Frontiers of Optoelectronics 13:4, pages 352-359.
Crossref
Crossref
Alessandro Rizzo, Simona Tavolari, Angela Dalia Ricci, Giorgio Frega, Andrea Palloni, Valeria Relli, Massimiliano Salati, Elisabetta Fenocchio, Annamaria Massa, Massimo Aglietta & Giovanni Brandi. (2020) Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. Cancers 12:11, pages 3256.
Crossref
Crossref
Luan Nguyen, John W. M. Martens, Arne Van Hoeck & Edwin Cuppen. (2020) Pan-cancer landscape of homologous recombination deficiency. Nature Communications 11:1.
Crossref
Crossref
Nai‐Jung Chiang, Ming‐Huang Chen, Shih‐Hung Yang, Chiun Hsu, Chia‐Jui Yen, Hsiao‐Hui Tsou, Yung‐Yeh Su, Jen‐Shi Chen, Yan‐Shen Shan & Li‐Tzong Chen. (2020) Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study. Liver International 40:10, pages 2535-2543.
Crossref
Crossref
Benjamin Goeppert, Trine Folseraas, Stephanie Roessler, Matthias Kloor, Anna‐Lena Volckmar, Volker Endris, Ivo Buchhalter, Albrecht Stenzinger, Krzysztof Grzyb, Marit M. Grimsrud, Barbara Gornicka, Erik von Seth, Gary M. Reynolds, Andre Franke, Daniel N. Gotthardt, Arianeb Mehrabi, Angela Cheung, Joanne Verheij, Johanna Arola, Heikki Mäkisalo, Tor J. Eide, Sören Weidemann, John C. Cheville, Giuseppe Mazza, Gideon M. Hirschfield, Cyriel Y. Ponsioen, Annika Bergquist, Piotr Milkiewicz, Konstantinos N. Lazaridis, Christoph Schramm, Michael P. Manns, Martti Färkkilä, Arndt Vogel, Kirsten M. Boberg, Peter Schirmacher & Tom H. Karlsen. (2020) Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology 72:4, pages 1253-1266.
Crossref
Crossref
Ines Malenica, Matteo Donadon & Ana Lleo. (2020) Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. Cancers 12:8, pages 2190.
Crossref
Crossref
Jingjing Li, Qing Wei, Xiaoying Wu, Jun Sima, Qi Xu, Mengmeng Wu, Fufeng Wang, Haibo Mou, Hanguang Hu, Jianguo Zhao, Da Li, Jinlin Hu, Lingnan Zhang, Xiu Zhu, Lei Chen, Cong Luo, Junrong Yan, Jiachen He, Yutong Ma, Yang Shao, Wei Wu & Jieer Ying. (2020) Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. Clinical and Translational Medicine 10:4.
Crossref
Crossref
Jung Wan Choe, Hyo Jung Kim & Jae Seon Kim. (2020) Survival improvement and prognostic factors in recent management of extrahepatic cholangiocarcinoma: A single-center study. Hepatobiliary & Pancreatic Diseases International 19:2, pages 153-156.
Crossref
Crossref
Pablo M. Santoro, Alejandra Sandoval-Bórquez & Alejandro H. Corvalan. 2020. Non-Coding RNAs. Non-Coding RNAs.
Artem Shiryaev, Polina Alekseeva, Kanamat Efendiev, Dmitry Yakovlev, Arkadii Moskalev, Elizaveta Kozlikina, Pavel KharnasIgor Reshetov, Vladimir Levkin & Victor Loschenov. (2020) Investigated spectral-fluorescent properties of endogenous porphyrins of the wild boar hepatobiliary system optimize the diagnostics and treatment of cholangiocarcinoma with FD and PDT. Optical Engineering 59:06, pages 1.
Crossref
Crossref
Alessandro Rizzo, Alessandro Di Federico, Angela Dalia Ricci, Giorgio Frega, Andrea Palloni, Rachele Pagani, Simona Tavolari, Mariacristina Di Marco & Giovanni Brandi. (2020) Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Cancer Control 27:1, pages 107327482098301.
Crossref
Crossref
Changjiang Lei, Xiulan Peng, Xiaojun Gong, Ying Fan, Shenglin Wu, Ning Liu, Lei Li, Jianbin Huang, Gang Zheng & Zhixiong Long. (2019) Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis. Aging 11:24, pages 12568-12580.
Crossref
Crossref